LAPTM4B-35 的过表达促进了肝癌在体内外的生长和转移。

Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.

机构信息

Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.

出版信息

Cancer Lett. 2010 Aug 28;294(2):236-44. doi: 10.1016/j.canlet.2010.02.006. Epub 2010 Mar 3.

DOI:10.1016/j.canlet.2010.02.006

PMID:20202745

Abstract

LAPTM4B-35, encoded by Lysosomal protein transmembrane 4 beta (LAPTM4B) is over-expressed in more than 71% of hepatocellular carcinomas (HCCs) and associated with prognosis of the patients. But the exact role and molecular mechanism in HCC have not been determined. In this study, we explored the effects and mechanisms of LAPTM4B-35 on tumor growth and metastasis in vitro and in vivo by overexpression and depletion of LAPTM4B in HCC HepG2 and Bel7402 cells. These findings suggest that overexpression of LAPTM4B-35 plays a critical role in the growth and metastasis of HCC, and LAPTM4B-35 may therefore be a therapeutic target for HCC.

摘要

LAPTM4B-35 由溶酶体蛋白跨膜 4β（LAPTM4B）编码，在超过 71%的肝细胞癌（HCC）中过表达，并与患者的预后相关。但是，其在 HCC 中的确切作用和分子机制尚不清楚。在这项研究中，我们通过在 HCC HepG2 和 Bel7402 细胞中转染 LAPTM4B 过表达和敲低，来探索 LAPTM4B-35 对 HCC 体外和体内肿瘤生长和转移的影响及其机制。这些发现表明，LAPTM4B-35 的过表达在 HCC 的生长和转移中起着关键作用，因此 LAPTM4B-35 可能是 HCC 的一个治疗靶点。